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Background: Markers of tumour biology may be valuable prognostic indicators after hepatic resection
of colorectal cancer liver metastases (CRLMs). Identification of the aggressiveness of these metastases
might inform the appropriateness of hepatic surgery.
Methods: Patients undergoing liver resection for CRLMs between January 2001 and July 2013 in
four tertiary hospitals were reviewed. A mathematical model to estimate CRLM doubling times was
constructed for patients with metachronous metastases. Tumour doubling time was investigated in
relation to the features of colorectal cancer, including KRAS status. The hazard rate for recurrence and
death following hepatectomy was explored through the Kernel-smoothed estimator.
Results: Of 1063 patients undergoing liver resection for CRLMs, 361 with metachronous metastases
undergoing single-stage hepatectomy were analysed. The mean doubling time in patients not receiving
chemotherapy between surgery for colorectal cancer and CRLM was 71⋅4days. Tumour doubling time
was shorter in patients with more advanced primary tumour stages, with mutant KRAS and in those who
did not receive chemotherapy. For fast-growing CRLMs (doubling time less than 48days), the risk of
recurrence was highest within the first postoperative year, and was about 7 per cent per month.
Conclusion: Primary features of colorectal cancer were linked to aggressiveness of CRLMs as measured
by doubling time.
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Introduction
Colorectal cancer is one of the most common malignan-
cies worldwide, accounting for at least one million new
cancer cases each year1. Spread to the liver occurs com-
monly, with roughly one-third of patients developing dis-
tant metastases2,3. Although surgical therapy for patients
with resectable colorectal liver metastases (CRLMs) offers
a 20 per cent possibility of cure 6–7 years after resec-
tion, many will not achieve long-term benefit3,4. As the
indications for liver-directed therapies broaden, the abil-
ity to identify patients likely to benefit from intervention is
important. Several morphological factors, such as number
and size of metastases, carcinoembryonic antigen (CEA)
level and the interval between primary tumour and the
recognition of hepatic metastases, have been shown to be
useful in predicting outcome5.
The potential aggressiveness of colorectal cancer is read-
ily evident when relapses occur early after resection of the
primary tumour, when it recurs in the liver with large or
bilobar metastases, and when there is little or no mea-
surable response to chemotherapy. Indicators of tumour
biology and how they might influence outcome are of
increasing interest. Mutation of the KRAS gene may be an
indicator of biological aggressiveness6–8. The relationship
between the growth rate of CRLMs and biological features
of colorectal cancer may provide additional information
related to outcome.
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The aim of the present study was to estimate CRLM
growth rate by assessing tumour doubling time in a con-
secutive series of patients with metachronous liver disease
who had undergone liver resection. Although assessment
of tumour growth rate requires at least two observations
of volumes, it is difficult to justify this for every patient
in a clinical setting. A mathematical approach was adopted
to overcome this problem to validate and investigate the
relationship of doubling time with clinical features and out-
comes after liver resection.
Methods
The study was approved by the Institutional Review Boards
and ethical committees of all participating centres.
Between January 2001 and July 2013, consecutive
patients undergoing liver resection for CRLMs with no
extrahepatic disease were identified from prospectively
developed databases at four Italian tertiary referral hos-
pitals for inclusion in the present analysis. Patients with
incomplete data, who had undergone preoperative portal
vein embolization, or in whom a two-stage hepatectomy
had been adopted were excluded. Patients presenting with
synchronous CRLMs were also excluded, retaining those
with metachronous disease. In this group, those with no
history of receiving chemotherapy in the interval between
primary colorectal cancer surgery and CRLM resection
were used for initial doubling time estimation.
Patients were deemed to have technically resectable dis-
ease when the metastases could be resected completely
and the future remnant liver volume was considered ade-
quate. Demographics, clinical data and CRLM features
were collected for each patient. The resection margin was
defined as R0Par when it was greater than 1mm and
as R1Vasc when the CRLM was detached from a major
vessel structure. Both were considered curative, as sug-
gested recently9,10. Otherwise, the resection margin was
defined as R1Par. Primary tumour characteristics, time
from resection of the primary tumour to liver resection
and the adoption of chemotherapy (either adjuvant after
primary colonic surgery or neoadjuvant before liver resec-
tion) were also detailed. When available, the mutational
status of KRAS, determined on the primary colorectal can-
cer, was recorded. The chemotherapy strategy was pre-
scribed by the oncologist in charge. Irinotecan, oxaliplatin,
capecitabine and monoclonal antibodies were offered to
patients after their approval by the Italian national health-
care system. Follow-up included clinical examination, esti-
mation of serum CEA level, and CT or MRI at 3, 6 or
every 12months, as determined by the oncologist and clin-
ical circumstances. Follow-up was carried out by assessing
the clinical records of the respective institutions or by tele-
phone contact with the referring clinician or patient.
Growth evaluation
The solution proposed relied in the concept of the gen-
esis of liver metastases from the deposition of unde-
tected/microscopic colorectal cancer tumour spheroids
that initiate CRLMmacroscopic growth. On this basis, the
following mathematical solution was adopted.
Patients with no history of chemotherapy in the interval
between primary colorectal cancer surgery and CRLM
resection were considered initially. The formula developed
Table 1 Characteristics of patients with metachronous colorectal
liver metastases
No. of patients
(n= 361)
Age (years)* 68 (60–74)
Age≥70 years 152 (42⋅1)
Sex ratio (M : F) 246 : 115
Primary tumour location
Right colon 136 (37⋅7)
Left colon 137 (40⋅0)
Rectum 88 (24⋅4)
Primary tumour T category
T1 12 (3⋅3)
T2 49 (13⋅6)
T3 253 (70⋅1)
T4 47 (13⋅0)
Primary tumour N category
N0 156 (43⋅2)
N1 131 (36⋅3)
N2 74 (20⋅5)
AJCC tumour stage (7th edition)
I 37 (10⋅2)
II 119 (33⋅0)
III 205 (56⋅8)
Primary tumour KRAS status
Wild-type 63 (17⋅5)
Mutant 59 (16⋅3)
n.d. 239 (66⋅2)
Chemotherapy between surgery for CRC and CRLM 212 (58⋅7)
Disease-free interval≥24months 207 (57⋅3)
Largest CRLM size (cm)* 3⋅0 (2⋅0–4⋅5)
No. of CRLMs* 2 (1–3)
R0 resection† 309 (85⋅6)
Extension of hepatectomy
Single or multiple wedges 160 (44⋅3)
Segmentectomy ± wedges 42 (11⋅6)
Bisegmentectomy ± wedges 58 (16⋅1)
Major hepatectomy ± wedges 101 (28⋅0)
Adjuvant chemotherapy after liver resection 226 of 329 (68⋅7)
Values in parentheses are percentages unless indicated otherwise; *values
are median (i.q.r.). †Includes 17 patients with R1Vasc resection margin.
n.d., Not determined; CRC, colorectal cancer; CRLM, colorectal liver
metastasis.
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Fig. 1 Distribution of doubling time values estimated in patients without and with chemotherapy. The mean doubling time in patients
with no chemotherapy between colorectal cancer surgery and metastasis resection was of 71⋅4 (95 per cent c.i. 62⋅8 to 79⋅9) days and
that in patients receiving chemotherapy was 78⋅0 (71⋅4 to 84⋅8) days. Corresponding median values are reported in Table 2
Table 2 Univariable regression analysis of primary colorectal cancer features in relation to estimated doubling time
Regression resultsDoubling time
(days)* Coefficient† P
Age (years)
<70 63⋅6 (44⋅3–95⋅4) 1⋅00 (reference)
≥70 56⋅4 (31⋅1–93⋅3) −0⋅09 (−0⋅22, 0⋅04) 0⋅184
Sex
F 61⋅3 (37⋅6–94⋅1) 1⋅00 (reference)
M 63⋅1 (41⋅3–94⋅7) 0⋅05 (−0⋅10, 0⋅19) 0⋅526
CRC location
Right colon 57⋅0 (35⋅4–88⋅9) 1⋅00 (reference)
Left colon 66⋅7 (39⋅8–93⋅4) 0⋅15 (0⋅00, 0⋅29) 0⋅044
Rectum 67⋅8 (40⋅4–97⋅1) 0⋅12 (−0⋅06, 0⋅30) 0⋅189
Primary CRC T category
T1 125⋅9 (65⋅2–154⋅8) 1⋅00 (reference)
T2 65⋅2 (45⋅6–103⋅6) −0⋅54 (−0⋅85, −0⋅23) 0⋅001
T3 61⋅7 (38⋅3–94⋅0) −0⋅61 (−0⋅89, −0⋅32) 0⋅001
T4 52⋅4 (31⋅9–72⋅0) −0⋅79 (−1⋅11, −0⋅48) 0⋅001
Primary CRC nodal status
N0 65⋅2 (44⋅2–103⋅3) 1⋅00 (reference)
N1 64⋅3 (39⋅9–93⋅5) −0⋅04 (−0⋅18, 0⋅10) 0⋅579
N2 52⋅8 (31⋅4–82⋅4) −0⋅28 (−0⋅46, −0⋅09) 0⋅003
AJCC tumour stage (7th edition)
I 72⋅5 (52⋅7–122⋅2) 1⋅00 (reference)
II 61⋅3 (39⋅6–91⋅6) −0⋅27 (−0⋅51, 0⋅04) 0⋅024
III 60⋅2 (37⋅2–95⋅6) −0⋅34 (−0⋅54, −0⋅13) 0⋅001
KRAS primary CRC
Wild-type 70⋅8 (40⋅2–122⋅7) 1⋅00 (reference)
n.d. 63⋅0 (44⋅1–95⋅6) −0⋅11 (−0⋅29, 0⋅08) 0⋅247
Mutant 49⋅5 (28⋅3–88⋅5) −0⋅33 (−0⋅58, −0⋅14) 0⋅001
No. of CRLMs
1 68⋅4 (44⋅2–103⋅6) 1⋅00 (reference)
2–3 58⋅1 (39⋅2–91⋅8) −0⋅05 (−0⋅19, 0⋅09) 0⋅448
>3 52⋅4 (33⋅6–82⋅0) −0⋅15 (−0⋅32, 0⋅02) 0⋅079
Chemotherapy between surgery for CRC and CRLM
Yes 65⋅6 (45⋅0–100⋅9) 1⋅00 (reference)
No 52⋅1 (35⋅9–94⋅7) −0⋅14 (−0⋅25, −0⋅03) 0⋅013
Values in parentheses are 95 per cent confidence intervals unless indicated otherwise; *values are median (i.q.r.). †Coefficients relate to logistic
transformation of doubling time. Time from primary colonic resection and colorectal liver metastasis (CRLM) size were not analysed as they are already
included in the calculation of doubling time. n.d., Not determined; CRC, colorectal cancer.
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Fig. 2 Nomogram of the relationships between primary colorectal cancer features and estimated colorectal liver metastasis doubling
times. Slow, intermediate and fast growth were based on the following tertiles for doubling time: fast, less than 48 days (120 patients);
intermediate, 48–82 days (120 patients); slow, more than 82 days (121 patients). The score was obtained through the least common
denominator of regression coefficients. Coefficients were as follows: T2, −0⋅53 (95 per cent c.i. −0⋅83 to −0⋅24; P= 0⋅001); T3, −0⋅56
(−0⋅83 to −0⋅29; P= 0⋅001); T4, −0⋅71 (−0⋅988 to −0⋅42; P= 0⋅001); N2, −0⋅14 (−0⋅29 to −0⋅99; P= 0⋅042); KRAS undetermined,
−0⋅06 (−0⋅25 to 0⋅13; P= 0⋅519); KRAS mutant, −0⋅32 (−0⋅57 to −0⋅07; P= 0⋅013); no chemotherapy, −0⋅17 (−0⋅30 to −0⋅04;
P= 0⋅010). WT, wild-type
by Schwartz, doubling time= t× ln2/(ln(V 2)− ln(V 1)),
was applied for estimation of doubling time, where t is the
time interval between measurements, and V 2 and V 1 are
the tumour volumes at the end and beginning of the time
interval11,12. V 2 was defined as the largest CRLM diameter
in the resected specimen. V 1 was obtained by assuming
that aggregates of colorectal cancer cells had already set-
tled in the liver at the time of primary tumour surgery, but
were as yet undetectable. A plausible range of CRLM sizes
that would exist before macroscopic diagnosis at the time
of colonic resection was assumed. Research suggested that
V 1 could be calculated from a starting size of a tumour
spheroid of 200 μm in radius, and a maximum diameter
of 6mm was taken on the basis that this represented the
lower limit for CRLM identification by common imaging
techniques13,14.
Between the two V 1 extremes (from 200 μm to 6mm),
a triangular distribution of V 1 was assumed as the best
approximation when the real distribution was unknown15.
Ten different random V 1 values within the applied range
were simulated. The variable t was calculated as the time
between primary colorectal cancer surgery, where unde-
tectable tumour aggregates were assumed to be already
present, and the time of liver resection, at which point the
tumour size provided the V 2 estimate. Doubling time was
calculated for each of the ten simulated values of V 1, main-
taining the value of t fixed as defined above. The average
doubling time value over the ten simulations was used as
the main outcome measure.
To provide plausibility and confirmation of the math-
ematical approach, obtained doubling time values were
compared with available published data. A systematic
search of PubMed and Institute for Scientific Informa-
tion (ISI) Web of Knowledge databases was performed
for articles published to 1 February 2018 relevant to
the tumour doubling time assessment of CRLM. The
PubMed database was searched using the following key-
words: ‘doubling time’[All Fields] OR ‘growth rate’[All
Fields] AND (colorectal[All Fields] AND (‘liver’[MeSH
Terms] AND/OR (‘neoplasm metastasis’[MeSH Terms]
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Fig. 3 Kernel-smoothed estimates of hazard rates over time for
death and recurrence
OR (‘neoplasm’[All Fields] AND ‘metastasis’[All Fields])
OR ‘neoplasm metastasis’[All Fields] OR ‘metastases’[All
Fields])). ISI Web of Knowledge was searched using the
following terms: ((TS=‘doubling time’ OR TS=‘growth
rate’) AND (TS=‘colorectal’ AND TS=‘metastases’))
AND document types: (Article). The search was limited
to human subjects and language limitations were imposed.
The reference list of identified studies was also searched
manually until no additional eligible trials could be identi-
fied. Additional articles were searched in Google Scholar
without retrieving any additional available study.
Statistical analysis
The Mann–Whitney test was used to compare doubling
time as the distribution was not normal. Natural logarithm
conversion of doubling time was used in univariable and
multivariable regression models. A nomogram to predict
doubling time was generated using coefficients from the
multivariable model through the least common denomina-
tor approach. Overall survival (OS) was calculated with the
Kaplan–Meier method using the log rank test from the
date of liver resection until the last follow-up visit (cen-
sored) or death. Recurrence-free survival (RFS) was calcu-
lated considering intrahepatic, extrahepatic or both types
of metastasis as the event and censoring the last follow-up
visit and deaths. The hazard rate (HR) of these survival
measures was explored by applying the Kernel-smoothed
estimator with Epanechnikov function16,17. This analytical
technique for lifetime data is flexible, model-free and
data-driven, so that no shape assumption is imposed other
than that of hazard function as a smooth function over
time18. For OS and RFS over the entire study population,
the Kernel-smoothed hazard estimator was initially unad-
justed for possible confounding factors, whereas when
analysing the relationship between doubling time and
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Fig. 4 Kernel-smoothed estimates of hazard rates for a recurrence
and b death in relation to colorectal liver metastasis doubling
time: fast growth, less than 48 days (120 patients); intermediate
growth, 48–82 days (120 patients); slow growth, more than
82 days (121 patients)
RFS, the estimator was adjusted at the mean of other
co-variables found able to modify prognosis17. Tumour
doubling time data retrieved from literature were pooled
using the random-effects model of DerSimonian and
Laird. Statistical analyses were done using STATA® soft-
ware (StataCorp, College Station, Texas, USA). P< 0⋅050
(two-tailed) was considered statistically significant.
Results
Of 1063 patients undergoing liver resection for CRLMs
without extrahepatic disease who were identified originally,
97 were excluded because of incomplete data, preoperative
portal vein embolization or a two-stage hepatectomy. A
further 605 had synchronous CRLMs, leaving 361 patients
who had undergone resection for metachronous disease
including 149 with no history of chemotherapy in the
© 2018 The Authors. www.bjsopen.com BJS Open 2019; 3: 186–194
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Table 3 Kernel-smoothed estimator of the monthly hazard rate of development of tumour recurrence after colorectal cancer liver
metastasis resection in relation to characteristics at liver surgery and postoperative time interval
Estimate of monthly hazard rate (%)*
0–6months 7–12months 13–24months 25–36months
CRLM doubling time
Slow growth 2⋅1 (1⋅8–2⋅5) 3⋅0 (2⋅7–3⋅2) 3⋅3 (3⋅0–3⋅4) 2⋅2 (1⋅7–2⋅9)
Intermediate growth 3⋅1 (2⋅8–3⋅5) 3⋅8 (3⋅6–3⋅9) 2⋅8 (2⋅5–3⋅5) 2⋅2 (1⋅8–2⋅5)
Fast growth 4⋅9 (4⋅0–5⋅9) 7⋅0 (6⋅6–7⋅2) 5⋅4 (3⋅1–6⋅7) 1⋅9 (1⋅4–2⋅5)
No. of CRLMs
1 3⋅3 (3⋅1–3⋅8) 4⋅5 (4⋅0–4⋅7) 3⋅5 (2⋅6–4⋅4) 2⋅3 (2⋅0–2⋅5)
2–3 3⋅2 (3⋅0–3⋅4) 3⋅9 (3⋅7–4⋅0) 3⋅2 (2⋅8–3⋅8) 1⋅8 (1⋅0–2⋅6)
>3 4⋅5 (4⋅3–4⋅7) 5⋅1 (4⋅8–5⋅3) 5⋅6 (5⋅0–5⋅9) 2⋅8 (0⋅8–4⋅7)
Resection margin
R0Par/R1Vasc 3⋅2 (2⋅9–3⋅5) 4⋅1 (3⋅8–4⋅3) 3⋅4 (2⋅6–4⋅0) 1⋅8 (1⋅5–2⋅5)
R1Par 5⋅0 (4⋅6–5⋅4) 5⋅8 (5⋅6–6⋅0) 5⋅1 (4⋅5–5⋅9) 4⋅8 (4⋅2–5⋅3)
Chemotherapy after CRLM surgery
Yes 2⋅8 (2⋅4–3⋅3) 4⋅3 (3⋅7–4⋅6) 3⋅7 (2⋅9–4⋅4) 1⋅9 (1⋅4–2⋅7)
No 5⋅8 (5⋅6–6⋅0) 5⋅4 (4⋅5–6⋅1) 3⋅4 (2⋅9–4⋅2) 2⋅4 (2⋅2–2⋅6)
*Values are mean (range). Each estimate was adjusted for the remaining variables. Slow, intermediate and fast growth of colorectal liver metastases
(CRLMs) were based on the following identified tertiles for doubling time: fast, less than 48 days (120 patients); intermediate, 48–82 days (120 patients);
slow, more than 82 days (121 patients). R0Par, resection margin greater than 1mm; R1Vasc, CRLM detached from major vessel structure; R1Par,
resection margin 1mm or less.
interval between primary colorectal cancer surgery and
CRLM resection. These patients were used for initial
doubling time estimation, the remaining 212 patients
being considered afterwards.
Baseline characteristics of the study population are shown
in Table 1. The mean doubling time value in the 149
patients was 71⋅4 (95 per cent c.i. 62⋅8 to 79⋅9) days. Based
on the literature search, 69 abstracts were screened. Of
these, 61 abstracts were considered not pertinent and eight
full texts were reviewed. Five studies19–23 were finally con-
sidered eligible for inclusion, reporting doubling time for
181 patients withCRLMs.The pooledmean doubling time
was 73⋅7 (95 per cent c.i. 43⋅9 to 103⋅5) days. The distribu-
tions of doubling time values for patients without and with
chemotherapy are depicted in Fig. 1.
The relationships between doubling time estimation and
features of the primary tumour and CRLMs are reported
in Table 2. In univariable analyses, doubling time was sig-
nificantly shorter in patients with right-sided colorectal
cancer, more advanced tumour stage, mutant KRAS, and
in those who did not receive chemotherapy between pri-
mary colonic surgery and CRLM resection. Multivariable
analysis confirmed stage, KRAS status and chemotherapy
as independent predictors of doubling time (Fig. 2).
For the subsequent survival analyses, doubling times
were divided into tertiles as follows: fast-growing
CRLMs, doubling time less than 48 days (120 patients);
intermediate-growing CRLMs, doubling time 48–82 days
(120 patients); slow-growing CRLMs, doubling time more
than 82 days (121 patients).
Survival analyses after resection of colorectal liver
metastases
Within amedian follow-up of 70⋅8months after liver resec-
tion, 243 (67⋅3 per cent) of the 361 patients developed
recurrence and 184 died (51⋅0 per cent). Of patients with
recurrence, 151 had intrahepatic recurrences (97 confined
to the liver, 54 both intrahepatic and extrahepatic). Median
overall survival for the entire cohort was 49⋅1months, and
1-, 3- and 5-year OS rates were 91⋅2, 58⋅8 and 45⋅0 per cent
respectively. Median RFS was 17⋅2months, and 1-, 3- and
5-year RFS rates were 62⋅8, 32⋅2 and 28⋅0 per cent respec-
tively. RFS was significantly reduced by shorter doubling
time (P< 0⋅001), higher number of CRLMs (P= 0⋅002),
lack of posthepatectomy chemotherapy (P= 0⋅002) and
positive resection margins (P= 0⋅006).
HRs over time for recurrence and death are plotted in
Fig. 3. The HR for recurrence was greatest (approximately
3⋅8 per cent per month) between months 9 and 16 after
surgery. The rate then started to decrease, becoming lower
than the risk of death from the 36th month onwards. By
contrast, the HR for death was greatest (about 1⋅8 per cent
permonth) between the 20th and 28thmonth after surgery,
and subsequently decreased.
Adjusted results on HRs for recurrence by doubling
time are depicted in Fig. 4a. Fast-growing tumours had
the maximum risk of recurrence (approximately 7 per
cent per month) between the ninth and 12th month after
surgery. The risk of recurrence then slowly decreased
until the 18th month, and then rapidly diminished.
Intermediate-growing tumours showed a similar temporal
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course, but with a monthly risk somewhat lower (about 4
per cent per month). In contrast, slow-growing tumours
showed their maximum risk of recurrence (about 3⋅3 per
cent per month) later in the postoperative period. After the
second year from surgery onwards, the HR for recurrence
was similar in these three groups.
The HR for death of fast-growing CRLMs was greatest
(about 2⋅7 per cent per month) between the 16th and 22nd
month after surgery, with another increase (around 2⋅0 per
cent per month) between the 29th and 39th month. The
HR for death then fell to the rates found for intermediate-
and slow-growing tumours (Fig. 4b).
All adjusted HRs for recurrence in relation to features
found during and after hepatectomy are reported inTable 3.
The presence of more than three CRLMs resulted in
a monthly HR greater than that that of less advanced
CRLMs in the first 2 years after surgery. Positive resection
margins led to a consistently higher HR over time com-
pared with the HR for negative resection margins. The
positive impact of postoperative chemotherapy was con-
fined to the first 6months after operation.
Discussion
The development of CRLMs, recurrence after liver resec-
tion and life expectancy depend on the complex interac-
tion between the primary colorectal cancer, treatments and
patient response.
In this study a significant relationship between doubling
time in the primary tumour and CRLM growth rate was
observed. The fact that T status, N category and KRAS
mutational status accounted for different CRLM doubling
times relies on the ‘seed and soil’ concept in stochastic and
deterministic ways24,25. From a stochastic point of view,
circulating tumour cells from the primary colorectal cancer
are already present in the liver at the time of primary
surgery, or might extravasate from the bloodstream at a
second or different time point. In both cases they can
either form macrometastases or remain dormant, often
for a long period of time24,26–28. The initial colorectal
cancer stages may involve the dissemination of solitary and
rare cell aggregates that cannot proceed to macroscopic
tumour development, resulting in long doubling times (for
example, T1 of 125⋅9 days). Conversely, more advanced
colorectal cancer stages could determine the release of
more tumour cell aggregates to seed the liver, with higher
probabilities that one (or more) of them will grow into
clinically detectable macrometastases, resulting in shorter
doubling times (for example, T4 of 52⋅4 days).
The deterministic point of view is based on the fact
that neoplasms contain genetically diverse tumour cell sub-
populations (genetic heterogeneity), each with a different
metastatic potential. In the initial stages of colorectal can-
cer, genetic subpopulations with low metastatic potential
may be less capable of progressing to macrometastases.
On the other hand, advanced colorectal cancers may be
more likely to give rise to macrometastases because fur-
ther genetic changes have appeared. The present findings
support this process. In fact, CRLMs from mutant KRAS
tumours grew faster than those derived from wild-type
colorectal cancers. TheKRASmutation has been associated
with an increased rate of primary colorectal cancer vascu-
lar invasion and decreased expression of regulatory mecha-
nisms, which result in faster proliferation, and an increased
rate of haematogenous spread29–31.
The complex interaction between tumour biology,
treatments and patient responses after liver resection
was evident in the variability of the monthly hazard of
recurrence and death in different subgroups. Fast-growing
tumours showed a peak in theHR for recurrence within the
first year after surgery (up to 7⋅0 per cent). This suggests
that aggressive colorectal cancers may have already seeded
in the liver and other organs, and that their aggressiveness
is maintained after hepatectomy32. This might account for
high rates of early recurrence25. This is supported by the
observation that slow-growing CRLMs showed a peak HR
late after surgery, usually at 1–2 years. Considering OS,
the peak HR for death was advanced by about 1 year for
fast-growing tumours with respect to the recurrence peak,
and by about 2 years for more indolent tumours. After this
time point, the recurrence HR for faster-growing tumours
returned to a level similar (2⋅2 per cent) to that of less
aggressive tumours (1⋅9 per cent), although the risk of
death remained higher.
The ability to achieve an R0 resection clearly affected
RFS. Almost all authors agree that R1 resection is asso-
ciated with a higher local recurrence risk9,10,33,34, but
this cannot be the sole cause of intrahepatic recurrence.
R1 resection may also indicate more diffuse intrahepatic
disease, which in turn leads to a more demanding surgical
procedure and a lower likelihood of obtaining an R0
resection35. This latter contention is supported by the
present results. If an R1 margin was simply due to surgical
failure, the HR for recurrence should be high early after
surgery and then decrease over time. Instead, it remained
consistently above that for R0 margins, suggesting that an
R1 margin reflects a more advanced tumour burden with
higher metastatic potential over the entire postoperative
time period.
The present study has limitations. First, only patients
with metachronous disease were considered. Estimation
of tumour doubling times in patients with synchronous
metastases would provide a more comprehensive picture.
© 2018 The Authors. www.bjsopen.com BJS Open 2019; 3: 186–194
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The second limitation relates to the reliability of the
doubling time estimate. The literature measuring CRLM
doubling time is more than 10 years old and, with mod-
ern treatments, comparability over such a long time
interval may not be valid19–23. Despite this, the present
mathematical model has been built on a sound scientific
rationale11–13, and findings in the cohort not receiving
chemotherapy after primary colorectal cancer resection
were in keeping with observed doubling time values in
earlier cohorts19–23.
The present study has provided a comprehensive estima-
tion of CRLM growth rates in patients with metachronous
liver involvement. It would seem reasonable to explore this
further in patients with synchronous metastases and to see
how doubling time is affected by different chemotherapy
regimens.
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